102 related articles for article (PubMed ID: 10425363)
1. Effects of renal insufficiency and aging on the pharmacokinetics of a phenethylamine class alpha(1A)-adrenoceptor agonist NS-49.
Mukai H; Morino A
Int J Pharm; 1999 Aug; 185(1):37-43. PubMed ID: 10425363
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 1st communication: absorption and excretion in rats after a single administration of 14C-NS-49.
Mukai H; Watanabe S; Morino A
Arzneimittelforschung; 1999 May; 49(5):434-40. PubMed ID: 10367106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of NS-49, a phenethylamine class alpha(1A)-adrenoceptor agonist, at therapeutic doses in several animal species and interspecies scaling of its pharmacokinetic parameters.
Mukai H; Watanabe S; Tsuchida K; Morino A
Int J Pharm; 1999 Sep; 186(2):215-22. PubMed ID: 10486440
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 2nd communication: Absorption and excretion in rabbits, dogs and monkeys after a single administration of 14C-NS-49.
Mukai H; Watanabe S; Morino A
Arzneimittelforschung; 1999 Jun; 49(6):527-32. PubMed ID: 10417870
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 3rd communication: metabolism in rats, rabbits, dogs and monkeys, and effects on hepatic drug-metabolizing enzyme activities in rats after repeated administration.
Mukai H; Watanabe S; Morino A
Arzneimittelforschung; 1999 Jul; 49(7):612-7. PubMed ID: 10442210
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 4th communication: tissue distribution, placental transfer and milk secretion of radioactivity in rats after a single oral administration of 14C-NS-49, and effects of repeated administration on its pharmacokinetics.
Dalrymple PD; Beeby TL; Mukai H; Chasseaud LF
Arzneimittelforschung; 2001; 51(5):394-401. PubMed ID: 11413740
[TBL] [Abstract][Full Text] [Related]
7. Renal excretion mechanism of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist.
Mukai H; Morino A
Biopharm Drug Dispos; 1999 May; 20(4):207-15. PubMed ID: 10440796
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist, in pigmented rats.
Koike T; Kitazumi H; Mukai H
Arzneimittelforschung; 2001; 51(5):402-7. PubMed ID: 11413741
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 1st communication: absorption, distribution and excretion after single administration of 14C-labeled compound to rats and dogs.
Nakamura A; Sugihara K; Hirota T; Morino A; Ezumi Y; Takaichi M
Arzneimittelforschung; 1997 Feb; 47(2):151-9. PubMed ID: 9079234
[TBL] [Abstract][Full Text] [Related]
12. Plasma leptin concentrations are only transiently increased in nephrectomized rats.
Landt M; Martin DR; Zeng J; Miller SB; Kohrt WM; Patterson BW
Am J Physiol; 1998 Sep; 275(3):E495-9. PubMed ID: 9725817
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
Nakamura A; Hirota T; Sugihara K; Morino A
Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
[TBL] [Abstract][Full Text] [Related]
15. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of NS-105, a novel cognition enhancer. 2nd communication: distribution and transfer into fetus and milk after single administration, and effects of repeated administration on pharmacokinetics and hepatic drug-metabolizing enzyme activities in rats.
Mukai H; Sugimoto T; Ago M; Morino A; Takaichi M; Ogawa Y; Seki H; Matsuura C; Esumi Y
Arzneimittelforschung; 1999 Dec; 49(12):977-85. PubMed ID: 10635441
[TBL] [Abstract][Full Text] [Related]
17. NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs.
Taniguchi N; Hamada K; Ogasawara T; Ukai Y; Yoshikuni Y; Kimura K
Eur J Pharmacol; 1996 Dec; 318(1):117-22. PubMed ID: 9007522
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats.
Takemoto F; Shinki T; Yokoyama K; Inokami T; Hara S; Yamada A; Kurokawa K; Uchida S
Kidney Int; 2003 Aug; 64(2):414-20. PubMed ID: 12846736
[TBL] [Abstract][Full Text] [Related]
19. NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors.
Obika K; Shibata K; Horie K; Foglar R; Kimura K; Tsujimoto G
Eur J Pharmacol; 1995 Nov; 291(3):327-34. PubMed ID: 8719417
[TBL] [Abstract][Full Text] [Related]
20. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
